- Report
- September 2022
- 82 Pages
Turkey
From €3221EUR$3,350USD£2,763GBP
- Report
- September 2022
- 80 Pages
South Africa
From €3221EUR$3,350USD£2,763GBP
- Report
- September 2022
- 76 Pages
Nigeria
From €3221EUR$3,350USD£2,763GBP
- Report
- September 2022
- 78 Pages
Myanmar
From €3221EUR$3,350USD£2,763GBP
- Report
- September 2022
- 74 Pages
Mexico
From €3221EUR$3,350USD£2,763GBP
- Report
- September 2022
- 73 Pages
Japan
From €3221EUR$3,350USD£2,763GBP
- Report
- September 2022
- 76 Pages
Israel
From €3221EUR$3,350USD£2,763GBP
- Report
- September 2022
- 76 Pages
Brazil
From €3221EUR$3,350USD£2,763GBP
- Report
- September 2022
- 77 Pages
France
From €3221EUR$3,350USD£2,763GBP
- Report
- September 2022
- 75 Pages
Germany
From €3221EUR$3,350USD£2,763GBP
- Report
- March 2023
- 75 Pages
Spain
From €3221EUR$3,350USD£2,763GBP
- Report
- February 2023
- 135 Pages
Africa
From €3606EUR$3,750USD£3,093GBP
- Report
- April 2020
- 120 Pages
Global
From €3519EUR$3,660USD£3,019GBP
- Report
- January 2020
- 130 Pages
Global
From €10572EUR$10,995USD£9,069GBP
- Drug Pipelines
- May 2018
- 79 Pages
Global
From €1923EUR$2,000USD£1,650GBP
- Report
- February 2022
- 40 Pages
India
From €2495EUR$2,595USD£2,141GBP
- Report
- February 2022
- 40 Pages
Saudi Arabia
From €2495EUR$2,595USD£2,141GBP
- Report
- March 2020
- 100 Pages
Global
From €4611EUR$4,795USD£3,955GBP
- Report
- July 2023
- 238 Pages
China
From €3846EUR$4,000USD£3,299GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$3,899USD£3,108GBP
The Anti Rheumatic market is a subset of the Immune Disorders Drugs market, which focuses on the treatment of rheumatic diseases. These diseases are caused by an abnormal immune response, which can lead to inflammation and joint pain. Anti Rheumatic drugs are used to reduce inflammation and pain, as well as to prevent further damage to the joints. These drugs can be administered orally, intravenously, or topically. Commonly used Anti Rheumatic drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic response modifiers.
Some companies in the Anti Rheumatic market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more